19249HAB9
Coherus Oncology, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops and sells immuno-oncology medicines — therapies that help the immune system find and attack cancer cells. Its flagship product, LOQTORZI, is an FDA-approved treatment for nasopharyngeal carcinoma, a type of head and neck cancer. Founded in 2010 by a longtime Amgen executive, the company spent over a decade as a maker of lower-cost biosimilar drugs before selling those products and renaming itself Coherus Oncology in 2025 to focus purely on cancer treatments. The name "Coherus" evokes the word "cohere," reflecting the company's focus on combining different therapies to fight cancer.
CONVERTIBLEUnderlying: CHRSCUSIP: 19249HAB9HealthcareUS1 derivative reporter
1.500% Convertible Senior Subordinated Notes due 2026
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
